Investing.comDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:36:32·⟳ 抓取 20:36:51 +19s·⚡ 决策 10-16 20:38:26 +1m35s·11.0 天前
Actinium制药宣布将在EANM 2026展示ATNM-400临床前实体瘤数据，属低强度会议预告
这是会议临床前（动物模型）数据的提前预告，不是人体临床结果，无近期业绩或注册里程碑；官方10月15日已发EANM新闻稿，10月15日股价已上涨8.76%提前反应；标的为~$1.06、市值约3300万美元、20日日均成交额仅约12.5万美元的超低价微盘股，盘前成交量仅几百股、买卖盘极薄（bid 85/ask 3），滑点与操纵风险高；真正的催化（10月19日FIH一期口头报告）尚未发生，现在追临床前预告没有正期望。
📄 原文Investing.com↗ 原文
Actinium to present preclinical data on ATNM-400 at EANM congress
Can AI avoid the boom-and-bust fate of past capital cycles? BofA weighs in NEW YORK - Actinium Pharmaceuticals, Inc. (N…
不做 Actinium Pharmaceuticals（ATNM.US）
会议临床前（异种移植模型）数据预告，NSCLC/CRC/卵巢癌均未进入临床，无近期收入或注册催化；官方10/15已发EANM新闻稿、当日股价已涨8.76%部分price-in；标的为$1.06、市值约3300万美元、日均成交额约12.5万美元的超低价微盘股，盘前仅几百股成交、买卖盘极薄，无法控制滑点和止损；真正催化是10/19的FIH一期口头报告，现在追临床前预告属见光前的高风险预演，无正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ATNM将在EANM展示ATNM-400的NSCLC/结直肠癌/卵巢癌临床前（异种移植模型）数据，但这些适应症均未进入临床、无近期商业化意义；消息前一日股价已涨8.8%，且为流动性极差的~1美元微盘股，预期差与可执行性均不足，回避。
消息传播链
- 公司10月15日发布EANM 2026口头报告新闻稿（主题为ATNM-400在前列腺癌的FIH一期研究），早于Investing.com预告稿一天市场反应:ATNM 10月15日收涨8.76%（0.9746→1.06）
- AI生成、编辑审核的二手预告稿，聚焦三场临床前数据展示（NSCLC/CRC/卵巢癌），无新增临床或商业事实
关键理由
- 无正期望做多腿：临床前xenograft数据不构成近期现金流或注册催化，真正价值催化（FIH一期人体数据）在10月19日才公布
主要风险
- 微盘低价股（$1.06、市值约3300万美元、日均成交额约12.5万美元）流动性极差，盘前仅454股成交，买卖价差大，无法以可控滑点建仓或止损
- 会议数据若被市场热炒可能出现题材脉冲，但属于事件兑现日（10/19）前后高波动的见光风险，不适合在预告日提前追入
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
公司近期曾收到NYSE American上市标准通知（5月SNMMI新闻稿标题并列披露），且为~1美元微盘、持续亏损（PE为负），存在低价股合规与再融资稀释风险；本次仅为临床前数据，无近期业绩支撑
检索:ATNM-400 EANM clinical data phase 1 prostate cancer October 2026 listing notice dilution financing 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不支持在预告日建仓，支撑AVOID
方向:未构建对齐先例：微盘biotech会议临床前数据预告样本异质性极高、受融资/流动性/散户情绪主导，无法形成可靠胜率
涨幅量级:无高相似对齐先例，不定tp/sl
形态:会议预告型微盘生物科技股常见预演后会议兑现日见光，但缺乏干净的同主体同相位首发先例，不据此做空
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`actinium pharmaceuticals atnm-400 eanm 2026 preclinical presentations | atnm-400 nsclc colorectal ovarian actinium-225 eanm vienna october 19`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件 - stock_quote 成功 stock_tools HTTP · 3,257 ms
{ - web_search 成功 doubao_search · 1,860 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM-400 EANM 2026 presentations press release；API SearchType:web）
原文全文
展开原文 · 2,027 字
Can AI avoid the boom-and-bust fate of past capital cycles? BofA weighs in
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) announced three presentations at the 39th Annual Congress of the European Association of Nuclear Medicine from October 17-21 in Vienna, Austria, featuring preclinical data on its Actinium-225 radiotherapy ATNM-400.
The presentations include one oral presentation and two e-posters covering ATNM-400 activity in non-small cell lung cancer, colorectal cancer, and ovarian cancer models, according to a press release statement.
In NSCLC models, ATNM-400 demonstrated antitumor activity as monotherapy and in combination with KRAS or ALK inhibitors, including in resistant models. The data extends earlier EGFR-mutant results.
In colorectal cancer, ATNM-400 showed monotherapy activity in SW620 xenografts and enhanced activity when combined with bevacizumab plus oxaliplatin in HCT15 xenografts, a model with moderate target expression.
In ovarian cancer models, ATNM-400 monotherapy produced antitumor activity, including in bevacizumab-refractory tumors.
The oral presentation, titled "ATNM-400 Elicits Durable Anti-tumor Responses in KRAS- and ALK-Driven NSCLC Models in a Mutation-Agnostic Manner," is scheduled for Monday, October 19 at 4:45-6:15 p.m. CEST in Hall G2.
Two e-posters will cover ATNM-400 in colorectal cancer models (EP-0163) and ovarian cancer models (EP-0176).
ATNM-400 is currently in clinical development for metastatic castration-resistant prostate cancer. The company stated the preclinical findings support development of ATNM-400 as both a standalone therapy and in combination with existing treatments across multiple solid tumor indications.
Actinium Pharmaceuticals develops targeted radiotherapies for solid tumors and hematologic malignancies. The company’s pipeline includes ATNM-400, Actimab-A, and targeted conditioning agents including Iomab-B.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) announced three presentations at the 39th Annual Congress of the European Association of Nuclear Medicine from October 17-21 in Vienna, Austria, featuring preclinical data on its Actinium-225 radiotherapy ATNM-400.
The presentations include one oral presentation and two e-posters covering ATNM-400 activity in non-small cell lung cancer, colorectal cancer, and ovarian cancer models, according to a press release statement.
In NSCLC models, ATNM-400 demonstrated antitumor activity as monotherapy and in combination with KRAS or ALK inhibitors, including in resistant models. The data extends earlier EGFR-mutant results.
In colorectal cancer, ATNM-400 showed monotherapy activity in SW620 xenografts and enhanced activity when combined with bevacizumab plus oxaliplatin in HCT15 xenografts, a model with moderate target expression.
In ovarian cancer models, ATNM-400 monotherapy produced antitumor activity, including in bevacizumab-refractory tumors.
The oral presentation, titled "ATNM-400 Elicits Durable Anti-tumor Responses in KRAS- and ALK-Driven NSCLC Models in a Mutation-Agnostic Manner," is scheduled for Monday, October 19 at 4:45-6:15 p.m. CEST in Hall G2.
Two e-posters will cover ATNM-400 in colorectal cancer models (EP-0163) and ovarian cancer models (EP-0176).
ATNM-400 is currently in clinical development for metastatic castration-resistant prostate cancer. The company stated the preclinical findings support development of ATNM-400 as both a standalone therapy and in combination with existing treatments across multiple solid tumor indications.
Actinium Pharmaceuticals develops targeted radiotherapies for solid tumors and hematologic malignancies. The company’s pipeline includes ATNM-400, Actimab-A, and targeted conditioning agents including Iomab-B.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
43c561f2e9· 2026-10-16 20:38 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前